Stock A006280 GC BIOPHARMA CORP.
Add to a list
To use this feature you must be a member
Log inSign up

All News GC Biopharma Corp.

Equities

A006280

KR7006280002

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
113,500 KRW -1.90% Intraday chart for GC Biopharma Corp. +1.43% -9.56%
May. 03 Green Cross Widens Q1 Loss, Sales Inch Up 2% MT
Mar. 20 GC Biopharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Green Cross Widens Q1 Loss, Sales Inch Up 2%
MT
GC Biopharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Ex-dividend day for final dividend
FA
GC Biopharma Corp. Announces US FDA Approval for ALYGLO (Immune Globulin Intravenous, Human-Stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)
CI
GC Biopharma Establishes mRNA Production Facility in Hwasun, Korea
CI
GC Biopharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
GC Biopharma Applies for MFDS Approval
CI
Immetas Therapeutics and GC Biopharma Announces Research Collaboration to Discover and Develop mRNA Therapeutics to Treat Autoimmune Diseases
CI
GC Biopharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Green Cross's Net Income Plunges in Q2
MT
GC Biopharma's "GC FLU" Obtains Vaccine Approval in Egypt
CI
GC Biopharma's "GC FLU" obtains vaccine approval in Egypt: First-ever approval of the company's quadrivalent flu vaccine on the African continent
PU
GC Biopharma Receives a Business License for the Construction of a Plasma Fractionation Plant and Technology Transfer in Indonesia
CI
GC Biopharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Green Cross Swings to Loss in Q1
MT
GC Biopharma Takes Over Catalyst Biosciences' Orphan Hematology Disorder Treatment Candidates
MT
GC Biopharma Receives WHO Pre-Qualification for BARYCELA
CI
GC Biopharma Receives WHO Pre-Qualification for Filling and Finish Plant in Ochang, South Korea
CI
Ex-dividend day for final dividend
FA
Curevo, Inc. announced that it has received $22.000002 million in funding from Janus Henderson Group plc, RA Capital Management, L.P., Adjuvant Capital, LP, GC Biopharma Corp. and other investors
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A006280 Stock
  4. News GC Biopharma Corp.